Breast Cancer
Cancer Type
Blood
Sample Type
10 Working Days
Turnaround Time ¹
ACTMonitor® Breast analyzes 8 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.
Precision Medicine to Plan Better Treatment
Every cancer is associated with a unique combination of genomic changes. Furthermore, different cells within a tumor may harbor different genomic abnormalities. Comprehensive genomic profiling can identify such changes in cell signaling pathways by detecting prognostic and predictive biomarkers. This information can then be used to facilitate treatment decisions. This process is known as precision medicine.
Why ACT Genomics?
Humane Process
Avoids multiple biopsies and the time cost associated with single-gene testing, as only a small specimen is required for the simultaneous detection of various genes.
Ideal Treatment
Nominates proper targeted options.
Smart Budgeting
Evaluates options before treatment, according to genomic information, to ensure success rate and avoid wasting of funds.
Learn More
What Can a Blood Test Do for Me?
Even the best plans need constant monitoring and adjustment to keep up with changes. The complexity of a cancer cell makes it like a multifaceted beast, where when one side is being controlled, another side rages. While cells sporadically release DNA into blood, if the DNA released from a tumor, circulating tumor DNA (ctDNA), can be captured and analyzed by cancer genomic profiling, more real-time clues from the cancer cell can be revealed. Through a simple blood test, drug resistance is no longer a hindrance, and this test can also detect any signals of relapse and serve as a non-invasive alternative option to surgical biopsies.
Common Problems Associated with Cancer Treatment
- Chemotherapy and surgery are the only options recommended by the NCCN guidelines or single-gene testing results
- Complications and metastases make it difficult to determine an appropriate drug
- Ineffective treatment and cancer relapse after targeted therapy
Diagnostic Solutions for Various Cancers
Through next-generation sequencing (NGS), ACTMonitor® Breast cancer monitoring testing decodes 8 genes to map drug options based on thorough clinical research, is not limited to a single clinical treatment guideline and determines the growth mechanism on a genomic level to provide more treatment strategy options with a higher success rate.
As single gene testing only provides very limited results, NGS genomic profiling can detect any special genomic mutations to result in a more effective treatment; if recurrence or metastases are found, treatment can be modified according to the NGS genomic profiling result to overcome drug resistance.
Who Is Suitable for ACTMonitor® Breast?
- Who are unable to undergo surgery
- Who have developed drug resistance
- With risk of cancer recurrence
- Who wish to monitor treatment response
Documentation
Disclaimers / Footnotes
- Turnaround time starts from the date of receipt of approved samples at our CAP-accredited laboratory.
